Vaxart, Inc. (VXRT) Earnings Call Transcripts
Vaxart, Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Vaxart, Inc. reported a significant revenue increase to $39.2 million, up from $20.9 million in the same quarter last year, primarily driven by a BARDA contract. The company achieved a net income of $5.2 million, or $0.02 per share, reflecting effective cost management. Management maintained guidance for a cash runway extending into Q2 2027, emphasizing ongoing clinical milestones and operational efficiency as key drivers for future growth.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $39.2 million (beat) |
| Net Income | $5.2 million (beat) |
| EPS | $0.02 (beat) |
| Cash Position | $61 million (positive) |
| Cash Runway | Into Q2 2027 (neutral) |
| R&D Expenses | Reduced (positive) |
Guidance from management
Vaxart expects its cash runway to extend into Q2 2027, maintaining this guidance while focusing on advancing clinical programs and operational efficiency.
What management said
We've gotten a large number of inquiries from lots of shareholders, and quite a few of them overlapped. So to start, we're putting the questions together according to subject. The first one: many people have been asking about what the main emphasis of the sentinel readout is, and whether that emphasis is safety rather than efficacy; also, questions about whether folks can still expect that readout, since early Q2 has...
Alright, thanks James. The following question is also directed at you. Is it Vaxart's view that there will be a significant distinction when it comes to immunogenicity, longevity, and cross-reactivity of the immune response, as well as viral — apologies, better load reduction, that could be observed even within a small cohort?
What analysts pressed on
Analysts expressed concerns regarding the delays in the COVID-19 trial data release, questioning if the timeline slipping indicates potential issues with data quality or collection processes. There were also inquiries about the company's ability to secure funding for the norovirus program.
Main topics on the call
- Revenue Growth — Vaxart's revenue for Q1 2026 reached $39.2 million, a substantial increase from $20.9 million in Q1 2025, driven largely by the BARDA contract. Management stated, "The growth in revenue was primarily driven by BARDA cont...
- Clinical Trial Updates — The Phase IIb COVID-19 trial's sentinel cohort is nearing completion, with management emphasizing that the primary focus is on safety and immunogenicity rather than efficacy. Dr. Cummings noted, "This cohort was not powe...
- Operational Efficiency — Vaxart has streamlined operations and reduced expenses, which contributed to a net income of $5.2 million for the quarter. CFO Jeroen Grasman stated, "We reduced our R&D and G&A expenses compared to the first quarter of ...
- Board Enhancements — The addition of Dr. James Breitmeyer to the Board is aimed at strengthening clinical and regulatory oversight as Vaxart approaches critical data milestones. CEO Steve Lo remarked, "His experience and track record... prov...
Read the full Vaxart, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Vaxart, Inc.
Vaxart, Inc. (VXRT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on OTC Pink Market and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 18 calls on record spanning August 8, 2022 to November 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 18 Vaxart, Inc. earnings call transcripts on record, spanning August 8, 2022 to November 6, 2026. Based on this history, Vaxart, Inc. reports quarterly. The most recent call on file is dated November 6, 2026. The full list is below — each row opens the transcript.
- Ticker
- VXRT
- Exchange
- OTC Pink Market
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 18
- First call
- August 8, 2022
- Most recent
- November 6, 2026
- Reporting cadence
- quarterly
| Quarter | Date | |
|---|---|---|
| Q3 FY2026 | Nov 6, 2026 | Read transcript → |
| Q2 FY2026 | Aug 7, 2026 | Read transcript → |
| Q1 FY2026 | May 8, 2026 | Read transcript → |
| Earnings Calls | Mar 12, 2026 | Read transcript → |
| Q3 FY2025 | Nov 13, 2025 | Read transcript → |
| Q2 FY2025 | Aug 13, 2025 | Read transcript → |
| Q1 FY2025 | May 13, 2025 | Read transcript → |
| Earnings Calls | Mar 20, 2025 | Read transcript → |
| Q3 FY2024 | Nov 13, 2024 | Read transcript → |
| Q2 FY2024 | Aug 8, 2024 | Read transcript → |
| Q1 FY2024 | May 13, 2024 | Read transcript → |
| Earnings Calls | Mar 14, 2024 | Read transcript → |
| Q3 FY2023 | Nov 2, 2023 | Read transcript → |
| Q2 FY2023 | Aug 3, 2023 | Read transcript → |
| Q1 FY2023 | May 4, 2023 | Read transcript → |
| Earnings Calls | Mar 15, 2023 | Read transcript → |
| Q3 FY2022 | Nov 8, 2022 | Read transcript → |
| Q2 FY2022 | Aug 8, 2022 | Read transcript → |